Document is current
Any future updates will be listed below
-
Authors
Duncan, L E
Ratanatharathorn, A
Aiello, A E
Almli, L M
Amstadter, A B
Ashley-Koch, A E
Baker, D G
Beckham, J C
Bierut, L J
Bisson, J
Bradley, B
Chen, C-Y
Dalvie, S
Farrer, L A
Galea, S
Garrett, M E
Gelernter, J E
Guffanti, G
Hauser, M A http://orcid.org/0000-0003-2667-5420
Johnson, E O
Kessler, R C
Kimbrel, N A
King, A
Koen, N
Kranzler, H R http://orcid.org/0000-0002-1018-0450
Logue, M W
Maihofer, A X
Martin, A R
Miller, M W
Morey, R A
Nugent, N R
Rice, J P
Ripke, S
Roberts, A L http://orcid.org/0000-0001-6393-8563
Saccone, N L
Smoller, J W
Stein, D J
Stein, M B
Sumner, J A
Uddin, M
Ursano, R J
Wildman, D E
Yehuda, R
Zhao, H
Daly, M J http://orcid.org/0000-0002-0949-8752
Liberzon, I http://orcid.org/0000-0002-4990-556X
Ressler, K J
Nievergelt, C M
Koenen, K C
- License Information
-
More Information
Article History
Received: 23 June 2016
Revised: 19 January 2017
Accepted: 15 February 2017
First Online: 25 April 2017
Competing interests
: Dr Kranzler has been an advisory board member, consultant or CME speaker for Indivior, Lundbeck and Otsuka. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative that is supported by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer and XenoPort. Dr Ressler is a founding member of Extinction Pharmaceuticals to develop D-Cycloserine to augment the effectiveness of psychotherapy. He has received no equity or income from this relationship within the past 3 years. Dr Ressler is also on the Scientific Advisory Boards for Resilience Therapeutics, Sheppard Pratt-Lieber Research Institute, Laureate Institute for Brain Research, The Army STARRS Project and the Anxiety and Depression Association of America. He holds patents for use of D-cycloserine and psychotherapy, targeting PAC1 receptor for extinction, targeting tachykinin 2 for prevention of fear and targeting angiotensin to improve extinction of fear. He receives or has received research funding from NIMH, HHMI, NARSAD, and the Burroughs Wellcome Foundation. In the past 3 years, Dr Dan J Stein has received research grants and/or consultancy honoraria from AMBRF, Biocodex, Cipla, Lundbeck, National Responsible Gambling Foundation, Novartis, Servier and Sun. Dr Murray Stein reports receiving in the past 3 years consultant fees from Actelion, Janssen, Dart Neuroscience, Healthcare Management Technologies and Pfizer. He also has an equity interest in Resilience Therapeutics and Oxeia Biopharmaceuticals. He has also received editorial honoraria from Biological Psychiatry and Up-To-Date. Dr Bierut is listed as an inventor on Issued US Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction. In the past 3 years, Dr Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Shire and Takeda; and has served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health-care research. In the past 3 years, Dr Liberzon has been a consultant for ARMGO Pharmaceutical, Sunovion Pharmaceutical and Trimaran Pharma. The remaining authors declare no conflicts of interest.
